You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • EP875 Novel clinical roles for BRCA1/2 germ-line status: 1) primary surgery is superior to neoadjuvant chemotherapy in sporadic but not in hereditary ovarian cancers; 2) Favorable anatomic pattern of relapses in BRCA1/2 mutation carriers

Article info

Article menu
Download PDFPDF
ePoster
EP875 Novel clinical roles for BRCA1/2 germ-line status: 1) primary surgery is superior to neoadjuvant chemotherapy in sporadic but not in hereditary ovarian cancers; 2) Favorable anatomic pattern of relapses in BRCA1/2 mutation carriers

Authors

Citation

Imyanitov E, Gorodnova T, Sokolenko A, et al
EP875 Novel clinical roles for BRCA1/2 germ-line status: 1) primary surgery is superior to neoadjuvant chemotherapy in sporadic but not in hereditary ovarian cancers; 2) Favorable anatomic pattern of relapses in BRCA1/2 mutation carriers
International Journal of Gynecologic Cancer 2019;29:A474.

Publication history

  • First published November 1, 2019.
Online issue publication 
March 03, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.